Company profile

Marengo Therapeutics, Inc.

Privately held: no public share price (Privately held immuno-oncology biotech launched 2021 with $80M from Apple Tree Partners; no IPO found. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.prnewswire.com/news-releases/marengo-therapeutics-launches-with-80m-from-atp-appoints-ceo-zhen-su-md-to-deliver-breakthrough-cancer-treatments-using-its-selective-t-cell-activation-repertoire-star-platform-301418075.html]) · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
STAR0602
Phase 2
TCR Vβ6/Vβ10 and IL-2 receptor (IL2R)Small molecule
Non-Small Cell Lung CancerHR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.